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Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple
myeloma patients ineligible for high-dose therapy
Thierry Facon, Jean-Yves Mary, Brigitte Pe ´gourie, MichelAttal, Marc Renaud, Alain Sadoun, Laurent Voillat, Ve ´ronique Dorvaux,
Cyrille Hulin, Ge ´rard Lepeu, Jean-Luc Harousseau, Jean-Paul Eschard, Augustin Ferrant, Michel Blanc, Fre ´de ´ric Maloisel, Hubert Orfeuvre,
Jean-Franc ¸ois Rossi, IsabelleAzaı ¨s, Mathieu Monconduit, Philippe Collet, BrunoAnglaret, Ibrahim Yakoub-Agha, Marc Wetterwald,
Houchingue Eghbali, Marie-Christine Vekemans, Herve ´ Maisonneuve, Jacques Troncy, Bernard Grosbois, Chantal Doyen, Antoine Thyss,
Je ´rome Jaubert, Philippe Casassus, Be ´atrice Thielemans, and Re ´gis Bataille, for the Intergroupe Francophone du Mye ´lome (IFM) group
Dexamethasone alone increases life ex-
pectancy in patients with relapsed mul-
tiple myeloma (MM); however, no large
randomized study has compared dexa-
methasone and dexamethasone-based
regimens with standard melphalan-
prednisone in newly diagnosed MM pa-
tients ineligible for high-dose therapy. In
the Intergroupe Francophone du My-
e ´lome (IFM) 95-01 trial, 488 patients aged
65 to 75 years were randomized between
4 regimens of treatment: melphalan-pred-
nisone,dexamethasonealone,melphalan-
dexamethasone, and dexamethasone–
interferon alpha. Response rates at 6
months (except for complete response)
were signiﬁcantly higher among patients
receivingmelphalan-dexamethasone,and
progression-free survival was signiﬁ-
cantly better among patients receiving
melphalan (P < .001, for both compari-
sons), but there was no difference in
overall survival between the 4 treatment
groups. Moreover, the morbidity associ-
ated with dexamethasone-based regi-
mens was signiﬁcantly higher than with
melphalan-prednisone, especially for se-
verepyogenicinfectionsinthemelphalan-
dexamethasone arm and hemorrhage, se-
vere diabetes, and gastrointestinal and
psychiatric complications in the dexa-
methasone arms. Overall, these results
indicated that dexamethasone should not
be routinely recommended as ﬁrst-line
treatment in elderly patients with MM. In
the context of the IFM 95-01 trial, the
standardmelphalan-prednisoneremained
the best treatment choice when efﬁcacy
and patient comfort were both consid-
ered. These results might be useful in the
context of future combinations with inno-
vativedrugs.(Blood.2006;107:1292-1298)
© 2006 by TheAmerican Society of Hematology
Introduction
In multiple myeloma (MM), melphalan and prednisone (MP) has
been used since the 1960s and still remains the most widely
accepted treatment option in elderly patients ineligible for high-
dose therapy.1 Slightly different dosages and schedules have been
used over the years without any demonstrated impact on survival.
More complex alkylating agent combinations have often added
toxicity and inconvenience without providing a survival advan-
tage.2 Since the 1990s, pulse dexamethasone (DEX) alone is also
frequently used, both at relapse and in untreated patients, although
very limited trial results are available.3,4 In the major study of 112
untreated patients, DEX had been considered to account for most of
the responses to VAD (vincristine, adriamycin, dexamethasone),
with a response rate of 43% and a lower incidence of serious
complications (27% for VAD versus 4% for DEX).4 Nevertheless,
the DEX toxicity, especially neurologic disturbances, psychiatric
complications, secondary diabetes mellitus, gastrointestinal prob-
lems, and infection susceptibility, could be a primary concern in
elderly patients. Only one recent study has compared melphalan
and dexamethasone (M-DEX) with MPand has concluded that MP
should remain the reference for comparison of new treatments
involving innovative drugs.5 Limited trial data are also available
regarding the dexamethasone–interferon alpha (DEX-IFN) combi-
nation. In a small nonrandomized study of newly diagnosed
patients, the addition of IFN (3 million units [MU]/m2/d) to DEX
achieved results similar to those with DEX alone.6 In another study,
DEX-IFN was given to patients who failed induction chemo-
therapy, and the outcome of these patients was improved with a
median survival of 48 months from the start of DEX-IFN.7 The
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in the context of a large randomized trial in elderly patients.
In June 1995, the Intergroupe Francophone du Mye ´lome
(IFM) group initiated a randomized clinical trial (IFM 95-01)
for newly diagnosed MM patients aged 65 to 75 years compar-
ing MP with dexamethasone-based regimens: M-DEX, DEX
alone, and DEX-IFN.
Patients, materials, and methods
Patients
Inclusion criteria were patients aged between 65 and 75 years and fulﬁlling
a diagnosis of stage II or III MM according to the Durie and Salmon
criteria.8 Durie and Salmon stage I MM patients could be enrolled if they
met one of the following criteria (deﬁning high-risk stage I patients):
presence of one lytic lesion on skeletal radiographs; bone pain with a
corresponding magnetic resonance imaging (MRI) lesion; hemoglobin less
than 120 g/L (12 g/dL) for males or 110 g/L (11 g/dL) for females,
associated to the presence of more than 25% plasma cells in bone marrow or
to M component over 30 g/L(IgG) or 25 g/L(IgA) or 1 g per 24 hours (light
chain). Patients were previously untreated (except the minimum dose of
radiotherapy to localized lesions required to relieve symptoms).
Patients were excluded if they met the criteria of primary amyloidosis or
had a prior history of another neoplasm or of seizure. Patients with
signiﬁcant cardiac, psychiatric (including mood alterations), or hepatic
dysfunction were also excluded as well as patients who were considered to
have a contraindication to high-dose steroids or who could be enrolled in
IFM concomitant high-dose therapy programs. Written, informed consent
was obtained from all patients before enrollment into the study.
Study design
This randomized, multicenter, parallel trial was carried out at 104 IFM centers in
France, Belgium, and Switzerland. Recruitment of patients took place between
June 1995 and September 1998. Patients were randomized per center to receive
MP, M-DEX, DEX, or DEX-IFN in a 1:1:1:1 ratio. Randomization was
performedpercenterbythebiostatisticalcenterusingpermutationtablesofsize4
or 8 according to the expected number of enrollments within each center.
Treatment schedules
MP. The regimen consisted of 12 6-week cycles of chemotherapy.
Melphalan (0.25 mg/kg) and prednisone (2 mg/kg) were given orally for 4
days. The neutrophil count must have reached 1.5  109/L and the platelet
count 100  109/L before full-dose chemotherapy was given. If the patient
did not meet these criteria, the treatment decision was reported 1 week later.
At week 7 of the start of chemotherapy, full-dose chemotherapy was given
if the previous criteria were met, a 50% melphalan reduction was performed
if the neutrophil count was between 1.0  109/L and 1.5  109/L or the
platelet count between 50  109/L and 100  109/L, and the decision was
discussed with the trial coordinator if these levels had not been reached.
DEX. The treatment consisted of 12 6-week cycles of dexamethasone,
40 mg/d, for 4 days beginning on days 1, 9, and 17 for the ﬁrst 2 cycles and
40 mg/d for 4 days beginning on day 1 for the next 10 cycles. The dose
could be reduced by 50% (20 mg/d) in case of toxicity.
M-DEX. The doses of melphalan and dexamethasone and dose
adjustments for side effects were the same as those presented for the MP
and dexamethasone regimens.
DEX-IFN. IFN alfa-2b (Schering-Plough) was administered subcuta-
neously at the dose of 3.0 MU 3 times weekly. It was started with
dexamethasone and stopped on day 42 of the last dexamethasone cycle. IFN
was permanently discontinued in the case of an emergence of cardiac
dysfunction or an occurrence of seizures or psychiatric complications.
Protocol doses of IFN were reduced by 20% to 50% in patients who
experienced signiﬁcant fatigue or other symptoms suggesting signiﬁcant
toxicity. The dose was subsequently reescalated if this was feasible.
Pamidronate. Pamidronate was supplied by Ciba-Geigy (Basel,
Switzerland) and then Novartis (Basel, Switzerland). Pamidronate was
administered intravenously at the dose of 90 mg within a 4-hour infusion
timeatday1ofeachcyleofchemotherapy(12injections).Patientswhohad
at diagnosis a creatinine serum level of 0.45 mM/L(50 mg/L) or more could
be enrolled in the trial but were excluded from pamidronate treatment.
Data collection and follow-up
At inclusion, usual clinical and biologic data were collected (Table 1).Visits
were planned after inclusion at 3 months, 6 months, and every 6 months
thereafter or up to treatment withdrawal due to treatment toxicity, MM
progression, patient consent withdrawal, or death. After treatment with-
drawal, patient status was regularly updated for MM progression and death.
At the time of the interim and ﬁnal analyses, a death certiﬁcate–based
search was used to update the date of death of patients when necessary.
End points and sample size
Primary end point was overall survival (OS). Secondary end points were
progression-free survival (PFS) and survival after progression, response
rates, and toxicities. A strategy was deﬁned a priori to compare survival
curves between the 4 treatment groups: step 1: comparison between
M-DEX and MP groups; step 2: comparison between DEX-IFN and DEX
groups; step 3: comparison between M (melphalan) groups (MP and/or
M-DEX) and DEX without M groups (DEX and/or DEX-IFN). For step 3,
if a previous comparison at step 1 or 2 was clearly not signiﬁcant (P  .20),
the corresponding groups were collapsed before the comparison at step 3.
Based on the primary end point, the number of patients to be randomized
was estimated to be 173 per group, as follows: median survival time of 24
months in the MP group, power of 80% to detect an increase in median
survival time of 12 months in a 2-sided test, type I error of 2% to ensure
approximately a global type I error of 5% taking into account the number of
comparisons according to the prespeciﬁed strategy, accrual time of 3 years
with additional follow-up of 3 years. Assuming that 70% of enrolled
patients could be analyzed, it was planned to enroll 800 patients.
Criteria of response
The achievement of any response required an improvement in bone pain
and performance status, correction of hypercalcemia, and no increase in
size or number of lytic bone lesions.Apartial response required a reduction
in the size of soft-tissue plasmacytomas, at least a 50% reduction in the
level of the serum monoclonal protein, and a reduction in 24-hour urinary
light chain excretion by 75% or more. A complete response required the
absence of the original monoclonal protein in serum and urine by
immunoﬁxation, less than 5% plasma cells in a bone marrow aspirate, and
disappearance of soft tissue plasmacytomas.
Progressive disease required one or more of the following: more than
25% increase in the level of the serum monoclonal protein, which must also
be an absolute increase of at least 5 g/L and conﬁrmed by at least one
repeated investigation, more than 50% increase in the 24-hour urinary light
chain excretion conﬁrmed by at least one repeated investigation, deﬁnite
increase in the size of existing bone lesions or soft-tissue plasmocytomas,
development of new bone lesions or soft-tissue plasmacytomas, or develop-
ment of hypercalcemia not attributable to any other cause. Patients not
meeting the criteria of either partial or complete response or progressive
disease were classiﬁed as having stable disease.
Statistical methods
Distributions of parameters evaluated at inclusion were compared globally
between treatment groups through the 2 test for categorical variables and
Kruskal-Wallis rank test for continuous variables. Curves for OS, PFS, and
survival after progression were calculated from randomization and from
progression for the latter using the Kaplan-Meier method.9 Time to event
(death, death or progression, and death after progression) was expressed as
median plus or minus SE. Relative hazards of death (relative risk [RR]),
progression or death, and death after progression, with 95% conﬁdence
interval (95% CI), were estimated through the proportional hazards
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prognostic value on OS from randomization, after stratiﬁcation on treat-
ment arm, through stepwise multivariate proportional hazards model, using
forward selection with likelihood ratio test.11 In these prognostic analyses,
each continuous variable was ﬁrst divided into 5 categories at approxi-
mately the 20th, 40th, 60th, and 80th percentiles. If the relative death rates
(ratio of the observed number of deaths to the expected number of deaths in
each category, assuming no variation of death rate across categories) in 2 or
more adjacent categories were not substantially different, these categories
were collapsed.12,13 If no clear pattern was observed, the median was used
as cutoff point. Usual limits (eg, 3 or 6 mg/L for c-reactive protein [CRP]
level) were also tested. As a consequence, 2 to 3 categories were used for
each continuous variable. After univariate analysis, all variables with a P
value below .20 were proposed in several steps to multivariate analyses,
ﬁrst including all variables with no missing values and then proposing
successively variables with an increasing number of missing values. At
each step, stability of the previously derived model was checked and no
further analysis was performed in case of instability. All analyses were
performed on an intent-to-treat basis with SPSS software (Chicago, IL).
The study was reviewed and approved by the institutional ethical committee
of the University Hospital of Lille. Preliminary results of the trial analyzed
to July 1, 1998, were reported in September 1999.14
Results
Five hundred patients were entered into the IFM 95-01 trial
between June 1995 and September 1998 with an interim analysis in
July 1998. Following the interim analysis, the data safety monitor-
ing board (DSMB) recommended stopping enrollment in the DEX
arm based on a striking disadvantage in terms of progression-free
survival (P  .001) of DEX as compared with M groups (MP and
M-DEX) and a trend on OS (P  .03). Stopping enrollment in the
DEX arm led to the decision to stop enrollment into the trial,
because the probability of demonstrating an advantage of M-DEX
orDEX-IFNascomparedwithMPwastoolow,takingintoaccount
the results available at the time of the interim analysis.15 Of these
500 patients, 12 were excluded from analysis because they did not
fulﬁll the above-mentioned eligibility criteria. The clinical, radio-
logic, and biologic characteristics of the 488 evaluable patients are
summarized in Table 1. Of those eligible patients, 122 were
allocated to receive MP, 118 to receive M-DEX, 127 to receive
DEX, and 121 to receive DEX-IFN. There was no difference in the
distributions of pretreatment characteristics between treatment
arms. No patients were lost to follow-up.
Effect of treatment on response, progression-free survival,
and survival
Complete responses were rare in all treatment arms, less than 2% at
6 months, with no difference between the 4 treatment groups. The
achievement of at least a partial response was more frequent with
M-DEX (70% at 6 months) as compared with other treatment
Table 1. Patient characteristics at enrollment
Characteristic Total MP M-DEX DEX DEX-IFN P *
No. patients 488 122 118 127 121 —
Female sex 239 (49) 53 (43) 63 (53) 63 (50) 60 (50) .48
Age
Median age, y 70 (67-72) 70 (68-72) 69 (68-72) 70 (67-73) 69 (67-72) .31
No. older than 70 y 200 (41) 55 (45) 45 (38) 55 (43) 45 (37) .52
Stage .48
I 52 (11) 14 (11) 13 (11) 16 (13) 9 (7) —
II 139 (28) 43 (35) 31 (26) 35 (28) 30 (25) —
III 293 (60) 65 (53) 72 (61) 75 (59) 81 (67) —
PCL 4 (1) 0 2 (2) 1 (1) 1 (1) —
B substage 43 (9) 13 (11) 9 (8) 7 (6) 14 (12) .32
M component .61
IgG 292 (60) 71 (58) 71 (60) 82 (65) 68 (57) —
IgA 132 (27) 36 (30) 29 (25) 34 (27) 33 (28) —
Bence Jones 44 (9) 13 (11) 12 (10) 6 (5) 13 (11) —
Other 19 (4) 2 (2) 6 (5) 5 (4) 6 (5) —
Kappa light chain† 289 (62) 78 (65) 67 (60) 74 (61) 70 (61) .85
Bone lesions .49
None 94 (19) 26 (21) 27 (23) 22 (17) 19 (16) —
Diffuse 217 (45) 46 (38) 53 (45) 61 (48) 57 (47) —
Others 176 (36) 50 (41) 38 (32) 43 (34) 45 (37) —
Hemoglobin level, g/dL 10.8 (9.4-12.0) 10.8 (9.2-11.9) 10.7 (9.5-12.0) 11.0 (9.7-12.1) 10.5 (9.1-11.9) .17
Platelet count,  109/L 232 (178-292) 223 (171-284) 245 (194-310) 232 (180-292) 231 (181-281) .27
Presence of circulating plasma cells 35 (7) 6 (5) 5 (4) 12 (10) 12 (10) .19
Serum 2-microglobulin level, g/L‡ 3.7 (2.6-5.5) 3.7 (2.6-5.9) 3.5 (2.4-5.2) 3.7 (2.7-5.5) 3.7 (2.8-5.5) .61
Creatinine level, mg/L 10.7 (9.0-13.0) 10.4 (8.9-12.7) 10.4 (9.0-13.0) 10.2 (8.6-13.0) 11.4 (9.4-14.0) .11
Serum calcium level, mg/L 95 (90-101) 95 (90-100) 95 (90-100) 95 (90-102) 96 (91-105) .37
Serum albumin level, g/L 38.0 (34.0-42.0) 38.0 (34.3-42.0) 39.0 (35.0-42.0) 37.0 (32.3-42.8) 37.0 (34.5-42.0) .43
LDH level, UI/L§ 295 (219-399) 291 (221-426) 339 (214-410) 301 (225-387) 285 (219-365) .68
CRP level, mg/L 5 (3-13) 5 (3-15) 5 (3-15) 5 (3-13) 5 (3-12) .99
Data are presented as no. (%) for qualitative characteristics, and as median (interquartile range) for quantitative characteristics.
PCLindicates plasma cell leukemia; —, not applicable; and LDH, lactico dehydrogenase.
*Chi2 and Kruskal-Wallis tests for qualitative and quantitative characteristics, respectively.
†n  468.
‡n  447.
§n  435.
n  449.
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cally signiﬁcant (P  .001) (Table 2).
After a median follow-up time of 82.8  1.6 months, the
median survival time for the whole series was 35.0  1.6 months
(415 deaths), and the median PFS time was 18.3  0.8 months
(473 progressions or deaths without progression). The median PFS
time was signiﬁcantly longer in M groups, 22.4  1.2 months, than
in DEX without M groups, 12.6  1.3 months (RR 1.55, 95% CI
1.30 to 1.86, P  .001), even if this difference did not convert into
a survival advantage for patients receiving M (Figure 1A-B).
Indeed, as described in Figure 1A, there was no signiﬁcant
difference in survival among the 4 treatment groups; or between
MP and M-DEX (RR  1.17, P  .27), between DEX and
DEX-IFN groups (RR  1.05, P  .75), and between DEX
without M groups (DEX and DEX-IFN) and M groups (MP
and M-DEX), with a survival time (median  SE) of 37.9  2.3
and 32.8  2.1 months, respectively, in the two latter groups
(RR  1.16, 95% CI 0.95 to 1.40, P  .14). This result was
concordant with a longer survival after the ﬁrst progression for
patients receiving DEX without M, 19.9  2.0 months, as
compared with those receiving M, 14.2  1.8 months (Figure
1C) (RR 1.30, 95% CI 1.04 to 1.62, P  .02). Second-line
treatments are summarized in Table 3. Most patients enrolled in
DEX without M groups received alkylating agent–based regi-
mens at time of ﬁrst relapse. In the late period of the study (after
January 1999), some relapsed patients received thalidomide,
which was equally distributed access arms (17 patients in MP,
M-DEX, and DEX; 10 patients in DEX-IFN).
Survival prognostic factors
Independent factors having an adverse impact on survival were a
high serum calcium level (2.75 mM or more [110 mg/L or more],
P  .001), an elevated serum 2-microglobulin level with 2 cutoffs
(more than 2.5 and more than 4.0 mg/L, P  .001), a poor World
Health Organization (WHO) index at inclusion (more than 1,
P  .001), a low platelet count (150  109/L or less, P  .002), a
high white blood cell count (more than 7.5  109/L, P  .02), and
a low hemoglobin level (90 g/L [9 g/dL] or less, P  .02). When
adjusting on these prognostic factors, the results obtained for the
OS comparisons between treatment groups were conﬁrmed, with
no difference between MP and M-DEX (RR  1.01, P  .93),
DEX and DEX-IFN (RR  1.10, P  .51), and DEX without M
and M groups (RR  1.12, 95% CI 0.92 to 1.38, P  .26).
Causes of death
Thirty-ﬁve deaths occurred in the ﬁrst 3 months (early deaths),
representing 7.2%  1.2% (mean  SE of Kaplan-Meier estimate
in the whole population). Early deaths were signiﬁcantly more
frequent(P  .004)intheDEXwithoutMgroups(10.5%  2.0%)
than in the M groups (3.8%  1.2%). Thirteen (37%) of these 35
early deaths were related to myeloma progression. Causes of death
in the ﬁrst 3 months of treatment were analyzed according to
treatment allocation (Table 4). Deaths related to MM progression
were more frequent in patients receiving DEX without M than in
patients receiving M (5% versus 0.5%, P  .003). Except for more
cancers, including myelodysplastic syndrome/secondary leukemia,
in M groups (4%) than in DEX without M groups (0.5%) (P  .02),
no differences were found between treatment groups with respect
to causes of death after 3 months.
Toxicity
No signiﬁcant differences in severe hematologic toxicity were
noted between MP and M-DEX; 18 patients (15%) and 20 patients
(17%) displayed grade 3-4 hematologic toxicity in MP and
Table 2. Response to treatment at 6 months in the IFM 95-01 trial
MP M-DEX DEX DEX-IFN P
No. patients 109 110 109 101 NA
At least partial response, % 41 70 40 42  .001
Complete response, % 1 3 1 1 .59
NAindicates not applicable.
Figure 1. Survival times. (A) OS from entry into the trial according to treatment. (B) Progression-free survival from entry into the trial according to treatment. (C) OS from time
of the ﬁrst progression according to treatment. O/N indicates number of events (deaths, deaths or progressions, deaths after progression)/total number of patients.
Table 3. Second-line treatment in the context of the IFM 95-01 trial
MP, no. M-DEX, no. DEX, no. DEX-IFN, no.
No. patients 122 118 127 121
DEX 20 4 1 1
VAD 35 26 8 4
Alkylating agent–based regimens 32 45 86 84
Other 5 6 4 4
None 28 33 24 24
Unknown 2 4 4 4
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DEX alone. In the DEX-IFN arm, IFN had to be stopped or reduced
(25% to 50% dose reduction) due to myelosuppression in 1 and 12
patients, respectively. In the DEX-IFN arm, 28 patients (23%) had
to stop IFN because of IFN-related (or at least partially related)
toxicity: arythmia in 2 patients, intolerance in 13 patients (with
refusal in 2 patients), refusal in 2 other patients, depression in 3
patients, severe confusion with hallucinations in 4 patients (which
could also be DEX related), seizure in 1 patient, hematotoxicity in
1 patient, hepatotoxicity in 1 patient, and miscellaneous in 1
patient. IFN was stopped between month 1 and month 12, at a
median time of 3 months. In addition, 30 patients (24%) had to
reduce by 20% to 50% at a median time of 3 months the IFN
dosage in relation to toxicity.
Severe nonhematologic toxicities are presented according to
treatment allocation in Table 5. Severe pyogenic infections were
more frequent in the M-DEX arm compared with other arms: 19%
versus 10%, 11%, and 9% among patients on MP, DEX, and
DEX-IFN, respectively (P  .01), and this was mainly due to a
higher incidence of pneumopathy. When hemorrhage, severe
diabetes, perforated diverticulum, and psychiatric complications
were considered together, they occurred less frequently in the MP
group (3%) as compared with the DEX-containing groups (11%)
(P  .007) but also when the comparison was restricted to DEX
alone (13%) (P  .007). Deep venous thrombosis (DVT)/
pulmonary embolism was equally distributed among arms (3% to
5%). When combining all severe nonhematologic complications,
the incidence was also lower in the MP group (16%) than in the
DEX-containing groups (28%) (P  .01) but also when the
comparison was restricted to M-DEX (31%) and to DEX alone
(27%) (P  .01 and .05, respectively).Atotal of 14 patients had
a solid tumor during trial follow-up (4 patients in MP, 4 patients
in M-DEX, 4 patients in DEX, and 2 patients in DEX-IFN
groups), the direct cause of death in 6 patients.
Discussion
In a large randomized trial comparing MP as the reference
treatment in elderly newly diagnosed MM patients with 3 different
treatments including DEX (M-DEX, DEX, and DEX-IFN), no
difference in OS was evidenced between the 4 treatment groups,
whereas the response rate appeared to be signiﬁcantly higher in
patients receiving M-DEX than in those receiving other treatments,
and PFS was signiﬁcantly better in patients receiving M than in
those receiving DEX without M. In addition, severe nonhemato-
logic toxicities were signiﬁcantly more frequent in patients receiv-
ing DEX regimens than in patients receiving MP, severe pyogenic
infections in patients receiving M-DEX, and hemorrhage, perfo-
rated diverticulum, psychiatric complications, or severe diabetes in
those receiving a DEX-containing regimen.
At the time the IFM 95-01 trial was initiated, the MP regimen
was still the reference treatment for elderly newly diagnosed MM
patients ineligible for high-dose therapy, but DEX or DEX-
containing regimens were considered of interest. Indeed,Alexanian
et al had reported a 43% response rate in newly diagnosed MM
patients treated with DEX alone, which was only 15% below the
response rate achieved with the VAD regimen with no differences
in survival.4 The study was not randomized, consisting of 112
consecutive patients with a median age of 60 years (the youngest
patient was 30 years of age) and a relatively short follow-up. In 88
patients who had failed to achieve response with induction
chemotherapy, Salmon et al had investigated the DEX-IFN regi-
men as a rescue treatment.7 These patients had a better average
outcome in terms of survival than did patients responsive to the
initial chemotherapy with a median survival of 48 months from
start of DEX-IFN, providing a rationale for a large evaluation of
DEX-IFN in newly diagnosed patients. In 1995 the M-DEX
combination had not been evaluated in a randomized study, and
only one recent publication has presented a comparison between
MPand M-DEX.5
The aim of the IFM 95-01 study was to compare, in elderly
patients ineligible for high-dose therapy, MP, M-DEX, DEX alone,
and DEX-IFN. This study represents the largest randomized trial
comparing MP with various DEX regimens before the availability
of new drugs such as thalidomide, bortezomib, or lenalidomide. It
is of importance to consider that these patients were between 65
and 75 years of age and that the study was performed in 104 centers
in France, Belgium, and Switzerland, adequately reﬂecting an
elderly unselected MM population referred to hospital in a recent
period of time. Moreover, the follow-up was rather long for a
clinical trial in MM, with a median of about 7 years.
Theachievementofatleastapartialresponsewassigniﬁcantlymore
frequent in the M-DEX arm (P.001) (Table 2). Response rates at 6
Table 5. Severe nonhematologic toxicities in the IFM 95-01 trial
analyzed by treatment allocation
Toxicity
Total, no.
(%) MP, no.
M-DEX,
no.
DEX,
no.
DEX-IFN,
no.
Severe pyogenic infections 59 (12) 12 22 14 11
Pulmonary 25 (5) 5 11 5 4
Septicemia 18 (4) 2 5 6 5
Other 16 (3) 5 6 3 2
Severe hemorrhage 10 (2) 2 3 5 0
Perforated diverticulum 8 (2) 0 3 1 4
Psychiatric complications 13 (2.5) 0 2 3 8*
Severe diabetes 16 (3) 2 2 8 4
DVT/pulmonary embolism 21 (4) 5 6 6 4
Any severe toxicity 121 (25) 20 36 34 31
The data were collected for 488 patients; for MP, n  122; for M-DEX, n  118; for
DEX, n  127; for DEX-IFN, n  121.
DVT indicates deep venous thrombosis.
*Including suicide in 1 patient.
Table 4. Causes of death in the ﬁrst 3 months during the IFM 95-01
trial analyzed by treatment allocation*
Causes of death
Total no.
patients MP M-DEX DEX DEX-IFN
Myeloma progression 13 1 0 3 9
Died unexpectedly at home; cause not
known 3 0 0 3 0
Pyogenic infection when tumor load not
immediately life threatening 12 3 1 5 3
Cardiac 2 1 1 0 0
Neurologic 1 0 1 0 0
Perforated diverticulum 1 0 0 0 1
Hemorrhage 1 0 0 1 0
Amyloidosis 1 1 0 0 0
MDS/secondary leukemia 0 0 0 0 0
Other cancer 0 0 0 0 0
Other causes 4 0 0 0 1†
The data were collected for 488 patients; for MP, n  122; for M-DEX, n  118; for
DEX, n  127; for DEX-IFN, n  121.
*Deaths in the ﬁrst month were as follows: MP, 1 patient; M-DEX, 1 patient; DEX,
5 patients; DEX-IFN, 6 patients.
†Suicide.
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without M and MPregimens (Table 2).Aslight increase in response rate
could not be excluded between 6 and 12 months for MP (41% at 6
months versus 50% at 12 months, data not shown), possibly reﬂecting
the presence of few slow responders in the MP arm. In the recent study
reported by the Spanish PETHEMAgroup (170 patients, median age 74
years, 87 receiving MP and 83 M-DEX), the partial response rates at 6
months were similar to those achieved in our study: 41% in both studies
for MP, 59% and 70% for M-DEX in the Programa para el Estudio de la
Terapeutica en Hemopathia Maligna (PETHEMA) study and the IFM
95-01 study, respectively. In both studies also, response rates achieved
by M-DEX were superior at 12 months to those achieved by MP.5
The disease control achieved by DEX and DEX-IFN was
clearly inferior to that achieved by M-containing treatments (MP
and M-DEX) in terms of PFS and MM-related deaths in the ﬁrst 3
months of treatment (Table 4; Figure 1B). Notably, 12 of 248
patients receiving DEX or DEX-IFN had MM progression and
death in the ﬁrst 3 months, whereas it was the case for only 1 of 240
patients receiving MP or M-DEX (P  .003). Nine of these early
deaths occurred in patients treated with DEX-IFN, and the possibil-
ity that IFN could promote MM progression in some rare patients
may not be ruled out. The PFS curves separated very early ina2b y
2 pattern whether the patients received M or not (Figure 1B). The
PFS advantage obtained in patients receiving M did not translate in
a better survival, because the OS was similar among arms (Figure
1A). In fact, patients initially treated with DEX or DEX-IFN had a
better average outcome after the ﬁrst progression (Figure 1C).
Second-line treatment consisted of alkylating agent–based regi-
mens in most of these patients, and these regimens appeared able to
rescue patients at relapse in the DEX and DEX-IFN arms (Table 3).
The IFM 95-01 provides the most complete database for DEX
toxicity in elderly MM patients. The severe nonhematologic
toxicities were signiﬁcantly more frequent in all DEX-containing
arms (Table 5). The incidence of serious DEX complications was
lower in the initial report ofAlexanian et al,4 but their patients were
younger (median age, 60 years versus 70 years in the IFM 95-01
study), including some very young patients. DEX-related toxicity
is in part age related, and our results are in line and extend the
results in the recent PETHEMA study. Our 19% incidence (22 of
118 patients) of severe pyogenic infections in the M-DEX arm was
similar to the 14% incidence of the PETHEMA study, which also
considered an elderly population. In addition, we found approxi-
mately 12% more severe nonhematologic complications in DEX-
containing arms than in the MP arm, a result comparable to the
more limited difference observed in the PETHEMA study (grade
3-4 toxicity during cycles 1 to 6 was 3% in the MP arm versus
12.5% in the M-DEX arm). Even when considering DEX alone or
M-DEX, the toxicity was higher to the one observed with MP. Of
note, in a recent Eastern Cooperative Oncology Group (ECOG)
study in elderly patients (median age, 65 years), DEX toxicity was
also a concern, with 17% of patients having a toxicity of grade 4 or
greater.16 The DEX-IFN arm had the same proﬁle for DEX toxicity
with a greater incidence of psychiatric complications and approxi-
mately one fourth of patients who had to stop IFN because of
toxicity.TheIFM95-01trialalsoprovidesusefulinformationregarding
the incidence of DVT in the context of MP- or DEX-containing
regimensbeforetheuseortheadditionofthalidomide.Overall,wehada
4% incidence of DVT, and this incidence was similar among the
different treatments. Recent results from ECOG also found a 3%
incidence of DVTusing DEX alone16
Taking into account efﬁcacy and toxicity results, we concluded
that in the context of the IFM 95-01 trial the standard M-prednisone
remained the best treatment choice in elderly patients. It does not
exclude that the use of DEX could be an option in individual
patients and selected situations such as renal failure, cord compres-
sion, or reduced blood count values. The addition of IFN to DEX
was of no beneﬁt in our trial, as also shown recently with
maintenance IFN in the US Intergroup trial.17 In the recent period,
DEX-containing regimens have been often designed for transplan-
tation candidates to avoid M exposure prior to stem cell harvest, but
they have been extrapolated to the nontransplantation population
without any convincing data. The results of the IFM 95-01 trial are
useful to design future combinations of innovative drugs, such as
thalidomide, bortezomib, or lenalidomide. These new drugs will
possibly add efﬁcacy to the conventional treatment but will also
add their own toxicity. Due to the toxicity of DEX or DEX-
containing regimens in elderly patients, the combination of these
innovative drugs with M should, in our opinion, be favored.
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